Reduced FDA Oversight Fuels Supplement Growth Amid Monsanto Lawsuits
What happened
The annual supplement industry in America is valued at $25 billion, a growth partly attributed to the Dietary Supplement Health and Education Act of 1994, which removed alternatives to medicine from U.S. Food and Drug Administration oversight. Separately, Monsanto faced a recent judgment regarding a weedkiller, a case the report described as a lucky one.
From science20.com
Why it matters
The removal of FDA oversight allowed companies to sell products making various claims, provided they noted that the FDA had not evaluated those claims. This regulatory environment, combined with public belief in alternatives to medicine, has driven significant market expansion in the supplement sector.
From science20.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
Keep exploring
The entities involved
Related events
- The House of Representatives killed a labeling law that was intended to protect biotech interests regarding GMO products.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.
- Litigation regarding FDA approval process.
- Congress and the Senate are considering legislation affecting FDA submissions and drug patent rights.